Bergen, Norway 21 April 2022

Today, Lifecare 2021 annual report is published. 2021 was marked by several
important milestones: 

o	Regulatory approval for first-in-human pilot clinical trials 
o	Restructuring the organization - controlling development operations
o	Reinforced Patent Protection and IP
o	Successful Capital Increase

The report is subject to approval by the company's general meeting on 6 May
2022.

Lifecare AS' management team will host an online presentation of the 2021 annual
results today at 13:00 - 14:00 CET. The presentation will also include
development outlook and assumptions related to the patient and market potential
for Sencell. The report and the presentation are attached to this release and
are also available on Lifecare's website. The basis for the Sencell market
potential can be downloaded at
https://lifecare.no/publications/sencell-market-assumptions-and-commercial-poten
tial-april-2022/ There will be a Q&A session following the management
presentation. 

The link to the webcast is available in the Investors section:
https://lifecare.no/events/webcast-annual-report-2021/. You can post questions
during the event or send them in advance to: kine.hereid@lifecare.no

Further information
Joacim Holter, CEO, Lifecare AS,  joacim.holter@lifecare.no, +47 40 05 90 40

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act. This stock exchange announcement was
published by Kine Hereid, Investor Relations at Lifecare AS, on 21 April 2022 at
11:00 CET.